FINWIRES · TerminalLIVE
FINWIRES

HKG:6855

2 stories mentioning HKG:6855Updated 12d ago

Every FINWIRES story that references HKG:6855, newest first.

Asia

Ascentage Pharma Files for $200 Million At-The-Market ADS Offering

Ascentage Pharma (HKG:6855) filed a registration statement with the U.S. Securities and Exchange Commission for a proposed at-the-market offering of up to $200 million in American depositary shares, according to a Sunday Hong Kong bourse filing.Net proceeds will be used to support the commercialization of olverembatinib and lisaftoclax, ongoing clinical trials, working capital, and general corporate purposes.The proposed offering is subject to Hong Kong Stock Exchange waivers from certain listing rules, and no ADSs will be sold until the waivers are granted.

HKG:6855
Asia

Ascentage Pharma Presents 17 Clinical Updates at European Hematology Meeting

Ascentage Pharma Group International (HKG:6855) presented 17 clinical updates from core assets at the 31st Congress of the European Hematology Association, including eight poster presentations, according to a Monday Hong Kong bourse filing.The presentations included data from ongoing clinical studies of olverembatinib and lisaftoclax at the conference held in Stockholm, Sweden, from June 11 to June 14.

HKG:6855

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:6855 in your portfolio
WheelAI
WheelAI
Analyze HKG:6855 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:6855